基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 原料药 抗肿瘤药 阿特珠单抗 MPDL3280A, RG7446
  • (Atezolizumab)Biosimilar Reference Antibody
  • (Atezolizumab)Biosimilar Reference Antibody
  • (Atezolizumab)Biosimilar Reference Antibody

1/3

(Atezolizumab)Biosimilar Reference Antibody

Atezolizumab
300 100μg 起订
湖北 更新日期:2026-03-06

武汉迈思生物科技有限公司

VIP1年
联系人:王爽
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

中文名称:
MPDL3280A, RG7446
英文名称:
Atezolizumab
CAS号:
1380723-44-3
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Humanised
偶联物:
靶点:
PDL1/CD274
免疫原:
PDL1/CD274
亚型:
IgG1
验证方法:
(Atezolizumab)Biosimilar Reference Antibody(GS40042) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

Atezolizumab is a fully humanized, engineered monoclonal antibody of the IgG1 isotype, designed as an immune checkpoint inhibitor. It specifically targets programmed death-ligand 1 (PD-L1), blocking its interaction with the PD-1 and B7.1 (CD80) receptors on immune cells. This blockade releases inhibitory signals on T cells, thereby reinvigorating the anti-tumor immune response. Developed by Genentech/Roche, it is approved for the treatment of multiple advanced cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), hepatocellular carcinoma (HCC), and urothelial carcinoma, often in combination with chemotherapy or other agents.


Atezolizumab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 100万以内
经营模式 试剂
主营行业 抗体,蛋白组学

MPDL3280A, RG7446相关厂家报价 更多

内容声明
拨打电话 立即询价